Routine ECG Screening May Help to Prevent CVD Events in Adults

2024-07-10
临床结果AHA会议
WEDNESDAY, July 10, 2024 -- Routine electrocardiogram (ECG) screening may help to prevent cardiovascular disease (CVD) events, according to a study published online July 1 in JAMA Internal Medicine.
Ryuichiro Yagi, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues conducted a nationwide cohort study to examine the association between ECG abnormalities and CVD outcomes in a population of individuals aged 35 to 65 years. A total of 3,698,429 individuals were enrolled in the nationwide health check program: 16.8, 3.9, and 1.5 percent had one minor ECG abnormality, two or more minor ECG abnormalities, and a major ECG abnormality, respectively.
The researchers found that compared with normal ECG, baseline ECG abnormality was independently associated with an increased incidence of the composite end points of overall death and CVD admission during a median follow-up of 5.5 years (incidence rates per 10,000 person-years, 92.7, 128.5, 159.7, and 266.3 for normal ECG, one minor ECG abnormality, two or more minor ECG abnormalities, and major ECG abnormality, respectively; adjusted hazard ratios, 1.19, 1.37, and 1.96, respectively, compared with normal ECG). An increased incidence of developing new major ECG abnormalities was seen in association with the presence and number of minor ECG abnormalities (incidence rates per 10,000 person-years, 85.1, 217.2, and 306.4 for normal ECG, one minor ECG abnormality, and two or more minor ECG abnormalities; adjusted hazard ratios, 2.52 and 3.61, respectively, compared with normal ECG).
"Further studies are needed to elucidate the role of routine ECG screening for early prevention of CVD events, along with optimal follow-up strategies for both major and minor ECG abnormalities," the authors write.
Abstract/Full Text
Editorial (subscription or payment may be required)
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI,赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台,以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。